WO2014028473A1 - Nouveaux sels de vilazodone et leurs formes à l'état solide - Google Patents

Nouveaux sels de vilazodone et leurs formes à l'état solide Download PDF

Info

Publication number
WO2014028473A1
WO2014028473A1 PCT/US2013/054707 US2013054707W WO2014028473A1 WO 2014028473 A1 WO2014028473 A1 WO 2014028473A1 US 2013054707 W US2013054707 W US 2013054707W WO 2014028473 A1 WO2014028473 A1 WO 2014028473A1
Authority
WO
WIPO (PCT)
Prior art keywords
vilazodone
salts
provides
xrd pattern
powder xrd
Prior art date
Application number
PCT/US2013/054707
Other languages
English (en)
Inventor
Helena Ceric
Masa Rajic Linaric
Marina Ratkaj
Original Assignee
Assia Chemical Industries Ltd.
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assia Chemical Industries Ltd., Teva Pharmaceuticals Usa, Inc. filed Critical Assia Chemical Industries Ltd.
Publication of WO2014028473A1 publication Critical patent/WO2014028473A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne des sels de vilazodone et leurs formes à l'état solide, des procédés de préparation de ces sels et de ces formes à l'état solide, et des compositions pharmaceutiques comprenant un ou plusieurs de ces sels et/ou une ou plusieurs de ces formes à l'état solide.
PCT/US2013/054707 2012-08-13 2013-08-13 Nouveaux sels de vilazodone et leurs formes à l'état solide WO2014028473A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682502P 2012-08-13 2012-08-13
US61/682,502 2012-08-13

Publications (1)

Publication Number Publication Date
WO2014028473A1 true WO2014028473A1 (fr) 2014-02-20

Family

ID=49485782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/054707 WO2014028473A1 (fr) 2012-08-13 2013-08-13 Nouveaux sels de vilazodone et leurs formes à l'état solide

Country Status (1)

Country Link
WO (1) WO2014028473A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
WO2023173182A1 (fr) * 2022-03-16 2023-09-21 Eurofarma Laboratórios S.A. Sel de docusate de vilazodone, procédé d'obtention, composition pharmaceutique et utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532241A (en) 1993-09-30 1996-07-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Piperidines and piperazines
WO2002102794A2 (fr) 2001-06-19 2002-12-27 Merck Patent Gmbh Formes polymorphes de chlorhydrate de 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine
US7799916B2 (en) * 2005-04-26 2010-09-21 Merck Patent Gmbh Process for the preparation of 5-(4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl)benzofuran-2-carboxamide
CN102267932A (zh) * 2011-06-15 2011-12-07 上海医药工业研究院 4-(5-氰基-1h-吲哚-3-基)丁基取代磺酸酯类化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532241A (en) 1993-09-30 1996-07-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Piperidines and piperazines
WO2002102794A2 (fr) 2001-06-19 2002-12-27 Merck Patent Gmbh Formes polymorphes de chlorhydrate de 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine
US7799916B2 (en) * 2005-04-26 2010-09-21 Merck Patent Gmbh Process for the preparation of 5-(4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl)benzofuran-2-carboxamide
CN102267932A (zh) * 2011-06-15 2011-12-07 上海医药工业研究院 4-(5-氰基-1h-吲哚-3-基)丁基取代磺酸酯类化合物及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
WO2023173182A1 (fr) * 2022-03-16 2023-09-21 Eurofarma Laboratórios S.A. Sel de docusate de vilazodone, procédé d'obtention, composition pharmaceutique et utilisation

Similar Documents

Publication Publication Date Title
US20150232457A1 (en) Crystalline forms of afatinib di-maleate
US8703967B2 (en) Crystal form of sunitinib malate
EP2603503B1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
US9630952B2 (en) Crystalline forms of afatinib di-maleate
US20170305936A1 (en) Solid state forms of crisaborole
WO2013078361A1 (fr) Formes à l'état solide de vilazodone et de chlorhydrate de vilazodone
EP3022209B1 (fr) Sel de potassium de dolutegravir
US9221815B2 (en) Solid state form of vemurafenib choline salt
US10377712B2 (en) Process for preparation of apremilast and novel polymorphs thereof
US9440971B2 (en) Solid state forms of vemurafenib hydrochloride
EP3430004B1 (fr) Formes solides de sels de nilotinib
US20100087459A1 (en) Forms of lapatinib compounds and processes for the preparation thereof
RU2384572C2 (ru) Соли арипипразола
US20200216427A1 (en) Solid state forms of entrectinib
WO2014028473A1 (fr) Nouveaux sels de vilazodone et leurs formes à l'état solide
WO2012071425A1 (fr) Formes à l'état solide de bésylate de sorafénib et procédés de préparation
WO2013181251A9 (fr) Sel de chlorhydrate de crizotinib sous forme cristalline
US20070032506A1 (en) Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
US20050020608A1 (en) Crystalline cetirizine monohydrochloride
WO2017035170A1 (fr) Formes à l'état solide de maléate de cédiranib
CN116041323A (zh) Sigma-1受体激动剂的酸式盐、其晶型及其制备方法和应用
CN117924287A (zh) 一种杂环取代的稠合γ-咔啉类衍生物的盐、晶型及其制备方法和应用
CN115521312A (zh) Adagrasib的固体形式及其制备方法
CN112830919A (zh) 苯并哌啶衍生物可药用盐及其制备方法
WO2015067223A1 (fr) Sel de l-tartrate de (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile et procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13782871

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13782871

Country of ref document: EP

Kind code of ref document: A1